Sector News

Novartis terminates $1bn Sandoz US deal with Aurobindo

April 2, 2020
Life sciences

Novartis and Aurobindo Pharma USA have signed a mutual agreement to terminate their deal covering the Sandoz US generic oral solids and dermatology businesses.

In September 2018, Novartis entered an agreement to divest parts of its Sandoz US business to Aurobindo Pharma USA for $900m in cash and potential earn-outs worth $100m.

Sandoz US business consists of a total of approximately 300 products, as well as other programmes in the development phase.

In addition, Aurobindo would have gained a dermatology development centre and three manufacturing facilities.

The deal was subject to closing conditions and the latest decision on termination comes after failing to secure the US Federal Trade Commission approval within timelines.

In a stock exchange filing, Aurobindo said: “Aurobindo today announced the mutual agreement with Sandoz to terminate the agreement to buy the Sandoz US generic oral solids and dermatology businesses from Sandoz.

“This decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines.”

Source: Pharmaceutical Technology

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend